Sudarshan pharma industries files RHP with BSE Limited
Sudarshan one of the few companies in India to manufacture API Vitamin B6.
Mumbai: Sudarshan Pharma Industries limited (“The Company”), one of the prominent players in the Pharma Industry, has filed its Red Herring Prospectus (“RHP”) with Stock Exchange BSE Limited. The company is engaged in trading and manufacturing of Specialty Chemicals, Intermediates & Active Pharmaceuticals Ingredients, outsource manufacturing facility, deal in Import and Exports, indenting and Supply in Specialty chemicals, API & its intermediate.
The Company has received permission to manufacture Vitamin B6 by the Government of India under the PLI Scheme, which makes Sudarshan one of the few companies in India to manufacture API Vitamin B6.
Moreover, the company manufactures their products from various suppliers in India and abroad regularly depending on the orders received from clients. Specialty chemicals and Intermediates have wide applications in the pharma, paint, food and adhesive Industry. They are also involved in Contract Manufacturing, outsource & Supply of Generic Pharma formulations and medicines to healthcare institutions, Government, NGOs and Hospitals. They carry about Ethical marketing of pharmaceutical formulations & products in the Domestic and International market through our own distribution network and Salesforce under its own brand.
The Company plans to raise through initial public offering issue of up to 68,62,400 equity shares, of face value ₹ 10.00 each (Equity shares) of Sudarshan Pharma Industries limited ( The company or the Issue ) for cash at a price ₹ [●] per equity share including a share premium of ₹ [●] per Equity share (The Issue Price) Aggregating to ₹ [●] Lakhs (“The Issue” of which 3,44,000 Equity shares aggregating to ₹ [●] Lakh will be reserved for subscription by market makers to the issue (The Market Maker Reservation portion ). The Issue less the market the Market Maker Reservation portion i.e., net issue of up to 65,18,400 Equity shares aggregating to ₹ [●] Lakhs (The “Net Issue”) The issue and the net will constitute 28.52% and 27.09% respectively of the post issue and paid-up equity share capital of the company.
PRICE BAND: ₹71.00 to ₹73.00 PER EQUITY SHARE OF FACE VALUE OF ₹10/- EACH AND THE ISSUE PRICE IS 7.1 TO 7.3 TIMES OF THE FACE VALUE AT THE LOWER PRICE BAND AND THE UPPER PRICE BAND RESPECTIVELY. BID CAN BE MADE FOR A MINIMUM OF 1600 EQUITY SHARES AND THE MULTIPLES OF 1600 EQUITY SHARES THEREAFTER.
The book running lead manager to the issue is GRETEX CORPORATE SERVICES LIMITED Registrar to the issue KFIN TECHNOLOGIES PRIVATE LIMITED.